EUVIMEDOpdag EUVIMED
Vergleichsstudie

Assessment of Rivaroxaban Plasma Concentration Using Chromogenic Anti‐Xa Assays and UHPLC–MS/MS in Chinese Patients With Atrial Fibrillation

Xiao-Qin Liu iD, Yi Gu, Yu-Fei Zhang, Wei Shen, Zhi-Chun Gu, Ming-Kang Zhong, Hong-Yan Ding, Chun-Lai Ma

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70088 ↗

At a glance

Vergleichsstudie in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Xiao-Qin Liu and 7 co-authors. Institution: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Atrial Fibrillation, Drug Monitoring, Factor Xa Inhibitors, Rivaroxaban. Cited 1 times so far (Crossref); 33 references. Funded by: Shanghai "Rising Stars of Medical Talent" Youth Development Program (Youth Medical Talents-Clinical Pharmacist Program), Shanghai Key Clinical Specialty Projects-Clinical Pharmacy.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Accurate quantification of rivaroxaban concentration is essential in some specific clinical situations. A prospective study was conducted to compare the rivaroxaban concentration measured by Zhenyuan anti‐Xa assay with that by reference methods (ultrahigh performance liquid chromatography with tandem mass spectrometry [UHPLC–MS/MS] and Biophen DiXal) in 243 plasma samples from 182 patients with non‐valvular atrial fibrillation. Zhenyuan anti‐Xa assays demonstrated less bias versus reference methods in samples with concentrations exceeding 50 μg/L compared to those in the < 50 μg/L group. Strong correlations were observed between Zhenyuan anti‐Xa assays and both reference methods (Pearson's correlation coefficient 0.976 and 0.988, respectively). However, Bland–Altman analysis revealed systematic underestimation by Zhenyuan anti‐Xa assays, with mean biases of 41.87 μg/L (vs. UHPLC–MS/MS) and 26.76 μg/L (vs. Biophen DiXal), particularly pronounced at higher levels. Rivaroxaban concentration in patients from clinical settings was with greater variability compared to the expected ranges. Patients taking underdose of rivaroxaban are more likely to have a trough concentration falling below the targeted therapeutic range.

Subjects

MeSH terms (MEDLINE)

Atrial FibrillationDrug MonitoringFactor Xa InhibitorsRivaroxabanAgedAged, 80 and overFemaleHumansMaleMiddle AgedChinaChromatography, High Pressure LiquidProspective StudiesReproducibility of ResultsTandem Mass SpectrometryEast Asian People

Author keywords

UHPLC–MS/MSZhenyuan anti‐Xa assaysatrial fibrillationrivaroxabantherapeutic drug monitoring

Substances

Factor Xa InhibitorsRivaroxaban

Authors and institutions

  • Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Laboratory Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Pharmacy, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.

ORCID profiles: Xiao-Qin Liu

Funding

  • Shanghai "Rising Stars of Medical Talent" Youth Development Program (Youth Medical Talents-Clinical Pharmacist Program)
  • Shanghai Key Clinical Specialty Projects-Clinical Pharmacy

Cite

APA

Liu, X. Q., Gu, Y., Zhang, Y. F., Shen, W., Gu, Z. C., Zhong, M. K., Ding, H. Y., & Ma, C. L. (2025). Assessment of Rivaroxaban Plasma Concentration Using Chromogenic Anti‐Xa Assays and UHPLC–MS/MS in Chinese Patients With Atrial Fibrillation. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70088

Vancouver

Liu XQ, Gu Y, Zhang YF, Shen W, Gu ZC, Zhong MK, et al. Assessment of Rivaroxaban Plasma Concentration Using Chromogenic Anti‐Xa Assays and UHPLC–MS/MS in Chinese Patients With Atrial Fibrillation. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70088

BibTeX
@article{Liu2025,
  author = {Liu, Xiao-Qin and Gu, Yi and Zhang, Yu-Fei and Shen, Wei and Gu, Zhi-Chun and Zhong, Ming-Kang and Ding, Hong-Yan and Ma, Chun-Lai},
  title = {Assessment of Rivaroxaban Plasma Concentration Using Chromogenic Anti‐Xa Assays and UHPLC–MS/MS in Chinese Patients With Atrial Fibrillation},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70088}
}
Start for free →